Skip to content

Effects of preemptive analgesia of intramuscular diclofenac versus pentazocine versus placebo on postoperative sequelae following mandibular third molar surgery.

Effects of preemptive analgesia of intramuscular diclofenac versus pentazocine on postoperative sequelae following mandibular third molar surgery: A randomized double-blind placebo-controlled study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202509876934174
Enrollment
90
Registered
2025-09-11
Start date
2024-01-10
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Health Surgery

Interventions

Preemptive analgesic administration
Preemptive placebo administration
Preemptive analgesic adminstration

Sponsors

Babajide Onanuga
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • Patients who were between 18 and 55 years of age that presented with an impacted mandibular third molar. • Patients who had signed the written informed consent form. • Patients who were literate and able to interpret their pain experience. • Impacted mandibular third molars with Pederson difficulty index less than or equal to a score 8 (moderate difficulty). • Patients with recurrent pericoronitis, unrestorable carious lesions, food packing, grossly fractured tooth, non-treatable pulpal pathology of an impacted mandibular third molar. • Patients classified as ASA I, using the American Society of Anaesthesiologists physical status classification (i.e. healthy individuals without systemic disease). • Patients who did not have active infection at the proposed surgical extraction site.

Exclusion criteria

Exclusion criteria: • Patients with clinically documented allergies to the drugs to be used in the study. • Patients who had been taking opioid and non-opioid analgesics within 48 hours prior to their intended surgical extraction. • Patients with clinically documented immunocompromised diseases such as uncontrolled Diabetes mellitus, HIV/AIDS or bleeding disorders. • Pregnant and breastfeeding patients. • Patients with peptic ulcer disease. • Patients with endodontically or periodontally compromised ipsilateral second molar also requiring its extraction.

Design outcomes

Primary

MeasureTime frame
Pain experience

Secondary

MeasureTime frame
Mouth opening;Facial swelling;Rescue analgesic ingestion

Countries

Nigeria

Contacts

Public ContactBabajide Onanuga

Lead researcher

jideonanuga1@gmail.com+2347037362110

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026